Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:ETON NASDAQ:PHAT NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.19-0.9%$2.29$1.09▼$3.40$243.16M0.64787,252 shs480,521 shsETONEton Pharmaceuticals$31.29-4.0%$26.08$13.09▼$35.66$857.03M0.82357,735 shs358,412 shsPHATPhathom Pharmaceuticals$11.10-2.0%$11.71$3.92▼$18.31$885.34M0.571.20 million shs834,488 shsSDGRSchrodinger$13.15-1.1%$12.12$10.94▼$27.63$970.73M1.571.38 million shs1.02 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+4.25%-8.30%+0.91%+78.23%ETONEton Pharmaceuticals0.00%+0.31%+41.57%+78.28%+64.51%PHATPhathom Pharmaceuticals0.00%-0.53%-3.16%-2.41%+181.84%SDGRSchrodinger0.00%+10.37%+12.81%+17.80%-37.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.19-0.9%$2.29$1.09▼$3.40$243.16M0.64787,252 shs480,521 shsETONEton Pharmaceuticals$31.29-4.0%$26.08$13.09▼$35.66$857.03M0.82357,735 shs358,412 shsPHATPhathom Pharmaceuticals$11.10-2.0%$11.71$3.92▼$18.31$885.34M0.571.20 million shs834,488 shsSDGRSchrodinger$13.15-1.1%$12.12$10.94▼$27.63$970.73M1.571.38 million shs1.02 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+4.25%-8.30%+0.91%+78.23%ETONEton Pharmaceuticals0.00%+0.31%+41.57%+78.28%+64.51%PHATPhathom Pharmaceuticals0.00%-0.53%-3.16%-2.41%+181.84%SDGRSchrodinger0.00%+10.37%+12.81%+17.80%-37.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.6370.19% UpsideETONEton Pharmaceuticals 2.40Hold$41.0031.16% UpsidePHATPhathom Pharmaceuticals 2.88Moderate Buy$25.00124.82% UpsideSDGRSchrodinger 2.33Hold$20.2553.18% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, SDGR, ETON, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $57.005/14/2026SDGRSchrodinger Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $17.005/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.004/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2026ALECAlector Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/8/2026SDGRSchrodinger KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$25.00 ➝ $20.003/27/2026PHATPhathom Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$16.00 ➝ $18.003/20/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$37.00 ➝ $52.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M11.23N/AN/A$0.09 per share23.67ETONEton Pharmaceuticals$79.95M10.71$0.00 per share6,287.62$1.12 per share27.91PHATPhathom Pharmaceuticals$175.11M5.06N/AN/A($4.22) per share-2.64SDGRSchrodinger$255.87M3.81N/AN/A$4.25 per share3.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)ETONEton Pharmaceuticals-$4.60M-$0.07N/A17.18N/A-1.70%-5.68%-1.49%8/6/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A7.13N/A-76.77%N/A-44.29%8/6/2026 (Estimated)SDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)Latest ALEC, SDGR, ETON, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10$0.05-$0.05$0.05$22.31 million$24.27 million5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 million2/26/2026Q4 2025PHATPhathom Pharmaceuticals-$0.09-$0.08+$0.01-$0.29$57.44 million$57.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25ETONEton Pharmaceuticals0.621.210.88PHATPhathom PharmaceuticalsN/A2.212.16SDGRSchrodingerN/A2.742.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ETONEton Pharmaceuticals27.86%PHATPhathom Pharmaceuticals99.01%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%ETONEton Pharmaceuticals16.49%PHATPhathom Pharmaceuticals9.33%SDGRSchrodinger10.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableETONEton Pharmaceuticals2027.39 million22.88 millionOptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableSDGRSchrodinger79073.82 million66.37 millionOptionableALEC, SDGR, ETON, and PHAT HeadlinesRecent News About These CompaniesSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 22, 2026 | businesswire.comMovano (NASDAQ:MOVE) vs. Schrodinger (NASDAQ:SDGR) Head to Head AnalysisMay 20, 2026 | americanbankingnews.comSchrödinger Balances Growth and Losses in Earnings CallMay 20, 2026 | tipranks.com7 Healthcare AI Stocks Under $50 With Huge Upside PotentialMay 18, 2026 | 247wallst.comSchrodinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Hold" by AnalystsMay 17, 2026 | americanbankingnews.comSchrodinger (NASDAQ:SDGR) Price Target Cut to $17.00 by Analysts at Morgan StanleyMay 15, 2026 | americanbankingnews.comSchrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comUBS Group AG Buys 489,059 Shares of Schrodinger, Inc. $SDGRMay 11, 2026 | marketbeat.comSchrodinger (NASDAQ:SDGR) Downgraded to Strong Sell Rating by Wall Street ZenMay 9, 2026 | marketbeat.comEarnings Update: Schrödinger, Inc. (NASDAQ:SDGR) Just Reported And Analysts Are Trimming Their ForecastsMay 8, 2026 | finance.yahoo.comSchrödinger (SDGR) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comA Look At Schrödinger (NasdaqGS:SDGR) Valuation After Q1 Earnings And Hosted AI Software PushMay 6, 2026 | finance.yahoo.comSchrödinger, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6, 2026 | seekingalpha.comSchrodinger Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comSchrödinger, Inc. (SDGR) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSchrödinger Earnings Call: Growth Now, Profits LaterMay 5, 2026 | tipranks.comSchrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comSchrodinger (NASDAQ:SDGR) Issues Earnings ResultsMay 5, 2026 | marketbeat.comSchrödinger Reports First Quarter 2026 Financial ResultsMay 5, 2026 | businesswire.comHere’s What the Street Thinks About Schrödinger (SDGR)May 5, 2026 | insidermonkey.comSchrodinger (NASDAQ:SDGR) Trading Up 5.8% - Here's WhyApril 28, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, SDGR, ETON, and PHAT Company DescriptionsAlector NASDAQ:ALEC$2.19 -0.02 (-0.90%) As of 04:00 PM EasternAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Eton Pharmaceuticals NASDAQ:ETON$31.29 -1.30 (-3.99%) As of 04:00 PM EasternEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Phathom Pharmaceuticals NASDAQ:PHAT$11.10 -0.23 (-2.03%) As of 04:00 PM EasternPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Schrodinger NASDAQ:SDGR$13.15 -0.15 (-1.13%) As of 04:00 PM EasternSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
